Index RUT
P/E -
EPS (ttm) -9.53
Insider Own 3.59%
Shs Outstand 12.41M
Perf Week 170.86%
Market Cap 320.59M
Forward P/E -
EPS next Y -12.11
Insider Trans -16.66%
Shs Float 11.96M
Perf Month 132.98%
Enterprise Value 288.62M
PEG -
EPS next Q -2.92
Inst Own -
Short Float 4.98%
Perf Quarter 133.33%
Income -133.04M
P/S 3.67
EPS this Y -19.62%
Inst Trans -
Short Ratio 0.42
Perf Half Y 89.76%
Sales 87.25M
P/B 23.34
EPS next Y -16.41%
ROA -40.79%
Short Interest 0.60M
Perf YTD 85.23%
Book/sh 1.11
P/C 1.47
EPS next 5Y -16.75%
ROE -189.46%
52W High 37.38 -30.87%
Perf Year 58.77%
Cash/sh 17.62
P/FCF -
EPS past 3/5Y 41.29% 25.49%
ROIC -74.51%
52W Low 6.48 298.77%
Perf 3Y -58.59%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -1.15% -3.00%
Gross Margin 74.12%
Volatility 35.92% 20.12%
Perf 5Y -92.50%
Dividend TTM -
EV/Sales 3.31
EPS Y/Y TTM 31.00%
Oper. Margin -160.27%
ATR (14) 3.53
Perf 10Y -86.19%
Dividend Ex-Date -
Quick Ratio 3.24
Sales Y/Y TTM -3.24%
Profit Margin -152.49%
RSI (14) 72.93
Recom 1.75
Dividend Gr. 3/5Y - -
Current Ratio 3.24
EPS Q/Q -27.65%
SMA20 83.90%
Beta 0.89
Target Price 90.67
Payout -
Debt/Eq 13.59
Sales Q/Q -51.66%
SMA50 118.07%
Rel Volume 1.70
Prev Close 25.76
Employees 61
LT Debt/Eq 12.00
Earnings May 08 AMC
SMA200 80.13%
Avg Volume 1.43M
Price 25.84
IPO May 03, 1994
Option/Short Yes / Yes
EPS/Sales Surpr. -40.39% -31.87%
Trades
Volume 2,431,935
Change 0.31%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-24-25 Reiterated
H.C. Wainwright
Buy
$6.50 → $120
Jun-24-25 Reiterated
BTIG Research
Buy
$60 → $100
Apr-11-25 Upgrade
Jefferies
Hold → Buy
$2
Mar-14-25 Upgrade
Oppenheimer
Perform → Outperform
$6
Jan-08-25 Initiated
B. Riley Securities
Buy
$4
Dec-10-24 Initiated
H.C. Wainwright
Buy
$6.50
Nov-04-24 Initiated
Piper Sandler
Overweight
$7
Sep-30-24 Resumed
BTIG Research
Buy
$4
Jun-28-24 Initiated
Rodman & Renshaw
Buy
$2
Nov-20-23 Resumed
JP Morgan
Underweight
Nov-09-23 Upgrade
TD Cowen
Market Perform → Outperform
May-10-23 Upgrade
Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade
Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade
JP Morgan
Neutral → Underweight
May-31-22 Resumed
Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade
Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade
Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade
Cowen
Outperform → Market Perform
Mar-14-22 Downgrade
William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade
Stifel
Buy → Hold
$24 → $5
Show Previous Ratings
Jun-30-25 04:02PM
02:21PM
Jun-28-25 08:15AM
Jun-25-25 06:45PM
12:20PM
11:30AM
Loading…
11:30AM
Jun-24-25 04:23PM
(Investor's Business Daily) +156.29%
10:54AM
10:40AM
09:07AM
(Investor's Business Daily)
07:30AM
Jun-23-25 04:30PM
May-13-25 05:00PM
May-09-25 02:29PM
(Thomson Reuters StreetEvents)
09:08AM
03:46AM
Loading…
03:46AM
May-08-25 06:25PM
05:19PM
(Associated Press Finance)
04:15PM
May-07-25 05:20PM
May-01-25 06:00PM
10:01AM
Apr-11-25 02:29PM
11:30AM
Mar-22-25 06:57PM
Mar-20-25 06:00PM
Mar-14-25 07:33AM
Mar-13-25 12:06PM
(Thomson Reuters StreetEvents)
03:09AM
Mar-12-25 08:30PM
07:00PM
Loading…
07:00PM
06:12PM
(Associated Press Finance)
04:15PM
Mar-05-25 06:00PM
Feb-27-25 10:59AM
Feb-26-25 07:00AM
Feb-24-25 07:00AM
07:00AM
Feb-10-25 07:00AM
Feb-07-25 09:35AM
Jan-31-25 09:55AM
Jan-10-25 07:00AM
Jan-07-25 09:24AM
Dec-07-24 12:00PM
Nov-18-24 03:30PM
Nov-08-24 02:30AM
Nov-07-24 05:40PM
04:36PM
(Associated Press Finance)
04:15PM
10:15AM
Nov-06-24 06:00PM
Nov-05-24 10:34AM
(Pharmaceutical Technology) +5.26%
Nov-04-24 01:44PM
08:30AM
Oct-31-24 06:00PM
Oct-29-24 09:00AM
Oct-17-24 12:07PM
Sep-25-24 03:30AM
Sep-03-24 09:00AM
Aug-13-24 12:00PM
Aug-09-24 10:58AM
Aug-08-24 05:55PM
04:49PM
(Associated Press Finance)
04:15PM
Aug-01-24 06:00PM
(PR Newswire) -5.22%
-5.51%
Jun-12-24 09:30AM
May-30-24 06:00PM
May-10-24 04:41PM
03:14PM
11:33AM
10:35AM
(Thomson Reuters StreetEvents)
May-09-24 05:39PM
(Associated Press Finance)
04:15PM
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
(Thomson Reuters StreetEvents)
Mar-04-24 05:30PM
04:51PM
04:42PM
(Associated Press Finance)
04:15PM
08:30AM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
(Associated Press Finance)
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Zalevsky Jonathan Chief R&D Officer May 19 '25 Sale 0.67 10,712 7,177 305,892 May 21 08:08 PM Wilson Mark Andrew Chief Legal Officer May 19 '25 Sale 0.67 9,996 6,697 314,296 May 21 08:07 PM ROBIN HOWARD W President & CEO May 19 '25 Sale 0.67 23,208 15,549 1,063,693 May 21 08:07 PM Zalevsky Jonathan Officer May 19 '25 Proposed Sale 0.67 10,712 7,191 May 19 03:49 PM Wilson Mark Andrew Officer May 19 '25 Proposed Sale 0.67 9,996 6,710 May 19 03:44 PM ROBIN HOWARD W Officer May 19 '25 Proposed Sale 0.67 23,208 15,580 May 19 03:40 PM Zalevsky Jonathan Chief R&D Officer Feb 19 '25 Sale 1.01 10,300 10,403 316,604 Feb 21 06:07 PM Wilson Mark Andrew Chief Legal Officer Feb 19 '25 Sale 1.01 11,040 11,150 324,292 Feb 21 06:06 PM ROBIN HOWARD W President & CEO Feb 19 '25 Sale 1.01 23,774 24,012 1,086,901 Feb 21 06:04 PM Wilson Mark Andrew Officer Feb 19 '25 Proposed Sale 1.01 11,040 11,137 Feb 19 03:27 PM ROBIN HOWARD W Officer Feb 19 '25 Proposed Sale 1.01 23,774 23,983 Feb 19 03:21 PM Zalevsky Jonathan Officer Feb 19 '25 Proposed Sale 1.01 10,300 10,391 Feb 19 03:18 PM Wilson Mark Andrew Chief Legal Officer Dec 23 '24 Sale 0.90 33,402 30,062 351,892 Dec 26 07:04 PM Wilson Mark Andrew Chief Legal Officer Dec 24 '24 Sale 0.89 16,560 14,738 335,332 Dec 26 07:04 PM Wilson Mark Andrew Officer Dec 24 '24 Proposed Sale 0.89 16,560 14,801 Dec 26 09:35 AM Wilson Mark Andrew Officer Dec 23 '24 Proposed Sale 0.90 33,402 29,898 Dec 23 03:21 PM Zalevsky Jonathan Chief R&D Officer Dec 19 '24 Sale 0.94 51,115 48,048 326,904 Dec 20 08:33 PM ROBIN HOWARD W President & CEO Dec 18 '24 Sale 0.99 85,035 84,185 1,110,675 Dec 19 09:08 PM ROBIN HOWARD W President & CEO Dec 17 '24 Sale 1.01 46,995 47,465 1,195,710 Dec 19 09:08 PM Zalevsky Jonathan Officer Dec 19 '24 Proposed Sale 0.94 51,115 48,063 Dec 19 03:12 PM ROBIN HOWARD W Officer Dec 18 '24 Proposed Sale 0.99 85,035 84,244 Dec 18 04:17 PM ROBIN HOWARD W Officer Dec 17 '24 Proposed Sale 1.01 46,995 47,338 Dec 17 03:29 PM Zalevsky Jonathan Chief R&D Officer Nov 19 '24 Sale 1.01 7,785 7,863 243,019 Nov 20 08:37 PM Wilson Mark Andrew Chief Legal Officer Nov 19 '24 Sale 1.01 6,407 6,471 218,856 Nov 20 08:36 PM ROBIN HOWARD W President & CEO Nov 19 '24 Sale 1.01 16,278 16,441 832,080 Nov 20 08:36 PM Zalevsky Jonathan Officer Nov 19 '24 Proposed Sale 1.01 7,785 7,878 Nov 19 04:10 PM Wilson Mark Andrew Officer Nov 19 '24 Proposed Sale 1.01 6,407 6,483 Nov 19 03:28 PM ROBIN HOWARD W Officer Nov 19 '24 Proposed Sale 1.01 16,278 16,472 Nov 19 03:17 PM Zalevsky Jonathan Chief R&D Officer Aug 19 '24 Sale 1.28 6,866 8,788 250,804 Aug 20 09:15 PM Wilson Mark Andrew Chief Legal Officer Aug 19 '24 Sale 1.28 5,651 7,233 225,263 Aug 20 09:15 PM ROBIN HOWARD W President & CEO Aug 19 '24 Sale 1.28 14,881 19,048 848,358 Aug 20 09:14 PM Wilson Mark Andrew Officer Aug 19 '24 Proposed Sale 1.28 5,651 7,211 Aug 19 04:13 PM ROBIN HOWARD W Officer Aug 19 '24 Proposed Sale 1.28 14,881 18,990 Aug 19 04:03 PM Zalevsky Jonathan Officer Aug 19 '24 Proposed Sale 1.28 6,866 8,762 Aug 19 03:45 PM